Twenty-three acute myelocytic leukemia (AML) patients with t(8;21) chromosomal abnormality, all classified as M2 (FrenchAmerican-British [FAB] classification), were investigated. Blastic cells from all patients were positive for the stem cellassociated antigens, CD34 and HLA-DR, and the immature myeloid antigens, CD13 and CD33. The nonblastic leukemic cells expressed the more mature myeloid antigens, C D l l b and CD15, with loss of the immature phenotype. The incidence of positivities for the stem cell-associated antigens, CD34 and HLA-DR, in t(8;21) AML cells was significantly higher in comparison with those in other AML showing granulocytic differentiation (M2 or M3). AML cells with t(8;21) also showed some phenotypic abnormalities. Fre-0 PRECISELY diagnose acute myelocytic leukemia T (AML), recent hematologic investigations have shown that it is necessary to consider information from various fields. Acute leukemia with a particular chromosomal abnormality often shows unique biologic and clinical characteristics.1,2 Advances in understanding the relationship between karyotype and other cellular properties have also suggested that some chromosome abnormalities are closely related to differentiational stages of hematopoiesis, such as 9;22 or 4;11 trans location^?-^ The 8;21 translocation, t(8;21)(q22;q22), is one of the most common karyotypic abnormalities in AML.'s~,~-~ This type of AML manifests characteristic cytologic and clinical features: prominent granulocytic maturation, low neutrophil alkaline phosphatase activity, eosinophilia, extramedullary infiltration, and favorable outcome. These characteristics led us to speculate that this chromosomal abnormality occurs at a particular stage of hematopoietic differentiation. Monoclonal antibody (MoAb) and molecular technologies have helped to determine the differentiational stage 
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of leukemic c e l l~.~,~-l~ However, the biologic information regarding t(8;21) AML cells remains insufficient.
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MATERIALS AND METHODS

Patients
When the frozen samples were used, leukemic cells with maturation were frequently eliminated. Values are percentages. Abbreviations: f, frozen samples; B, blastic cell fraction; W, whole mononuclear cell fraction; nB, nonblastic cell fraction; G, germ line; NT, not tested.
French-American-British (FAB) criteria for AML,12 and were classified into one of five AML subgroups, from M1 to M5.
Karyotype analysis was performed on aspirated BM cells, as previously described. 13 The chromosomes were classified according to an International System for Human Cytogenetic Nomenclature (ISCN) (1985) .
Heparinized peripheral blood (PB) or BM samples were obtained with informed consent from all patients. Mononuclear cells were separated from the samples by Ficoll-Hypaque density gradient centrifugation. Stocked samples at -196°C in RPMI 1640 medium supplemented with 20% fetal calf serum (GIBCO Lab, Chargrin Falls, OH) and 10% dimethyl sulfoxide were also used as needed after Ficoll-Hypaque recentrifugation.
Before immunostaining, the cells were treated with 5% of heat-aggregated human AB serum for blocking of binding due to receptors for the IgG Fc portion (FcyR). CDllb (recognized by OKMl), CD13 (by MCS2), CD15 (by LeuMl), CD33 (by My9), and CD34 (by MylO) were tested as myeloid cell markers; CD2 (by Tll), CD5 (by Leul), CD7 (by TP40), CD3 (by Leu4), CD4 (by Leu3a), and CD8 (by Leu2) as T-cell markers; and Igs, CD19 (by Leu12 and/or B4), CD20 (by Leul6), and CD22 (by Leul4) as B-cell markers. CDlO and HLA-DR were examined by J5 and Karyorypic study.
Zmmunophenoyping.
OKIal, respectively. Goat antimouse Ig-fluorescein isothiocyanate (GAM-FITC) was used as the secondary reagent. Phycoerythrinconjugated Leu12 (PE-Leul2) was used for double staining together with fluorescein-conjugated MCS2 (FITC-MCS2) or FITCMy9. PE-Leu12 was also applied to double staining using cells previously stained by indirect immunofluorescence. Immunorosetting using antimouse Ig-coated sheep erythrocytes was used for cytochemistry. l4 Cytoplasmic CD19 (cCD19) and cCD22 were tested on acetonefixed cytospin smears and visualized using alkaline phosphatase (AP) substrate (Vector Labs, Burlingame, CA) after treatment with biotin-labeled horse antimouse antibody (Vector) and APconjugated avidin (Dakopatts, Glostrup, Denmark). Terminal deoxynucleotidyl transferase (TdT) was tested on methanol-fixed cytospin smears by indirect immunofluorescence using rabbit anti-TdT antibody or anti-TdT MoAb.
At least 5,OOO cells in each sample were evaluated in a surface marker study using a Cytoron flow cytometer (Ortho Diagnostic System, Tokyo, Japan). More than 200 cells were examined for cCD19, cCD22, and TdT by Olympus light or immunofluorescence microscopy (Tokyo, Japan). Samples were considered positive for an MoAb if greater than 15% of cells showed specific labeling above control.
For
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TP40 and MCS2 were kindly provided by Drs R. Ueda (Aichi Cancer Center, Nagoya, Japan) and E. Tatsumi (Kobe University, Kobe, Japan), respectively. The Leu series and Mylo were purchased from Becton Dickinson Lab (Mountain View, CA); My4, My9, B4, J5, anti-TdT MoAb, and GAM-FITC from Coulter Inc (Hialeah, FL); OKMl and OKlal from Ortho: FITC-conjugated rabbit antihuman Igs F(ab2) from Hoechst Co (Marburg. Germany); and rabbit anti-TdT antibody from Bethesda Research Lab (Gaithersburg, MD). Whole mouse Ig, IgGI. and lgG2 used as the controls were purchased from Chemicon Int Inc (Temecula, CA).
High molecular weight DNA and total RNA were extracted from the mononuclear cell fractions. Southern and Northern blotting were performed, as previously described.Is
Reverse mnscriprion plymeruse chain reaction (RT-PCR). Expression of CD19 and CD20 genes was examined by RT-PCR, as previously described.I6 Total RNA (3 pg) was applied as a template for cDNA synthesis. After RT, one-quarter of the reaction mixture was diluted with PCR buffer containing 50 pmol each of upstream and downstream primers and 2.5 U Taq polymerase (Perkin Elmer Cetus, Norwark, CT). The 
denaturing, 2 minutes at 60°C for annealing, and 2 minutes at 72°C for extending. The amplified cDNA products were electrophoresed in 4% agarose gel and visualized using ethidium bromide.
DNA 
RESULTS
Thc patient groups consisted of 26 MI, 58 M2, 24 M3, 22 M4, and 17 M5. Thc t(8;21) abnormality was obscrvcd in 23 paticnts, various typcs of othcr abnormalitics in 54, and a normal karyotypc in 70 (Tablc I). All t(8;21) paticnts wcrc M2. A scx chromosomc was missing in 12 paticnts, and additional abnormalitics in scvcn.
The FcyR was sufficicntly blockcd with hcat-aggregated human AB serum, as shown in Figs 1 and 2. M2 and M4 cclls wcrc widcly sprcad on thc cytogram of flow cytomctry according to the morphologic heterogeneity (Fig 2) . In principlc, wc focused on thc blastic fraction of thc cytograms from M2 and M4 to clarify thc phcnotypc of thc lcukcmic stcm cclls. Blasts in t(8;21) AML paticnts ranged from 18% to 87% of thc freshly isolatcd mononuclcar cclls.
CD13 wcrc positivc for 23 of 24 t(8;21) AML paticnts, CD33 for IO, CD34 for all, and HLA-DR for all (Tablc 2).
Positive perccntagcs of CD13, CD34, and HLA-DR wcrc highcr in thc blasts than in thc nonblastic cells, whcrcas thosc of CDllb and CD15 increascd in the lattcr. CD33 cxprcssion on thc blasts varicd among samples. CD19 cxprcssion was shown on blasts from 18 t(8;21) paticnts, and thc positive pcrccntagc ranged from 19% to Karyorypes of AML patients.
Immunophenoype of AML cells with t(8;21).
93%. Immunofluorcsccncc intcnsity of the CD19 cxpression was variablc, and was wcakcr than on prc-B acute lymphocytic leukemia (ALL) cclls in gcneral. When there wcrc low numbcrs of blasts, CD19 expression was often vcilcd in autofluoresccncc of wholc mononuclcar cells (Fig  2) . CD19 cxprcssion also could bc dctectcd by immunocytochemistry (Fig 3B) . The CD19+ blasts expressed CD34 (Figs 1 and 3A) . and some of thcm wcrc POX positive ( Fig  3C) . CD20, cCD22, CDIO, and T-ccll antigens were not dctccted in any samplcs. TdT was positivc in only one t(8;21) patient. CD19 cxprcssion was found among 10 AML paticntswithout t(8;21), 5 MI, 3 M2,l M3, and 1 M5 (Tablc CD19 messenger RNA (mRNA) was detected as a 485-bp band in all 6 CD19+ t(8;21) samplcs cxamincd by RT-PCR (Fig 4) , and was detected as an approximately 2-kb band in all 5 samples cxamincd by Northern blotting (Fig 5) . One of the CD19 mRNA+ samples (from casc 22 in Table 2 ) was judged as CD19-according to the phcnotypic critcria, but the fluoresccncc intcnsity of CD19 (mean channel, 43.8) was slightly strongcr than that of thc control (39.6). CD20 mRNA was not found in any of thcsc samples (Fig4). No CD19 mRNA was obscrvcd in CD19-AML without t(8;21).
Immunogenotypes of AMI, cells with the t(8;21) abnormality. All t(8;21) samples cxamined had germline IgH and TCR gcncs (Tablc 2). IgH gcne rearrangements were observcd in thrcc CD19+ M1 patients without t(8;21). One of the samplcs also had Ig light chain, TCRy, and TCRP gcnc rcarrangcmcnts.
Phenotypic differences among AML cells showing granulocytic maturation in relation to chromosomal abnormalities.
).
CD19and CD20gene erpression. Table 3 shows the phenotypical differences among AML cellswith granulocytic maturation, M2, and M3. Blasts from all patients had more than two myeloid antigens together with POX and CAE expression. CD34 and HLA-DR positivity rates were higher in t(8;21) AML patients than in other M2 and M3 patients (P < .01). There was no difference of frequency of CD33+ samples among t(8;21) M2, other M2, and M3, but the CD33 expression on blasts in t(8;21) samples was significantly weak (P < .01). All t(8;2l) samples were negative for CDllb.
Blasts from 17 of 35 M2 patients without t(8;21) expressed the T-cell antigen, CD7. No significant differences in CD34 and HLA-DR positivities were seen between t(8;21) patients and those that were CD7+ M2. CDllb and TdT positivity rates were higher in the CD7+ M2. Blasts from two M2 patients without t(8;21) coexpressed CD7 and CD19 (Table 3 ).
DISCUSSION
We have described the phenotypic characteristics of t(8;21) AML. The blasts expressed stem cell antigens, CD34 and HLA-DR,19 whereas the nonblastic cells had more mature antigens, CDllb and CD15, with loss of the immature antigens. Nonblastic (granulocytic) cells from t(8;21) patients were distinguishable from normal granulocytes by the morphologic abnormalities on the cytospin smears such as the presence of Auer rod& This finding indicates that t(8;21) AML consists of heterogenous populations along granulocytic differentiation not only morphologically but also immunophenotypically. The high incidence of positivities for CD34 and HLA-DR in t(8;21) AML suggests that this translocation occurs through the process of early hematopoietic development as well as t(9;22) and t(8;21) in the same metaphase,2l sequential changes from t(9;22) to t(8;21),2* and t(8;21) and llq23 abnormalities in independent clones have been rep0rted.2~
CD33 is a useful marker of myeloid progenitorsa and is commonly expressed on AML cells.9J0 However, t(8;21) AML cells expressed less CD33 than other M2 and M3 cells. This phenomenon might reflect the existence of an abnormal regulation of gene expression of myeloid antigens in t(8;21) AML as well as in the abnormal cytochemical reactions. 7.8 It is of interest that blasts from 18 of 24 t(8;21) patients expressed the early B-cell antigen, CD19,= without other B-cell properties. Immunocytochemical and RNA studies of CD19 confirmed these results. CD19 transcripts from a CD19-t(8;21) patient suggests that a small amount of CD19, which could not be judged as positive by flowcytometry, might be expressed on the blasts. CD19 expression is thought to be more common in t(8;21) AML, and to be helpful for making a diagnosis of t(8;21) AML in M2.
The frequency of CD19 expression in AML varies among previous reports.26-28 The weak expression of CD19 on To explain the cross-lineage phenotype, two different hypotheses have been proposed: lineage infidelity29 or lineage promiscuity.3° In t(8;21) AML, CD19 was expressed on blasts with stem cell phenotype. Most CD19+ AML without t(S;21) also showed an immature phenotype, the rearranged IgH genes, and/or t(9;22) abnormality, as previously With regard to the expression of other lymphocyte antigens, some AML cells share the pan-T-cell antigen, CD7.",31,32 CD7+ AML cells are phenotypically immature and are thought to be part of a continuous spectrum to CD7+ CD4-CDS-ALL cells that show prominent multiple differentiati0n.3~ Indeed, there were no differences in CD34 and HLA-DR positivity rates between t(S;21) AML and CD7+ AML. Thus, AML cells expressing at least CD19 or/and CD7 are more likely to preserve the properties of multipotential stem cells. In this sense, CD19 expression in t(8;21) AML might be a sign of retaining multipotentiality.
The phenotype of t(8;21) AML cells suggests that this translocation occurs in a discrete differentiation stage of early hematopoiesis and relates to the low CD33 expression and cytochemical abnormalities. Recently, breakpoint region genes of e21 translocation have been i~o l a t e d .~~,~~ Further molecular genetic investigations of the breakpoint genes are expected to clarify the phenotypic events in this type of leukemia.
